Akebia Therapeutics (AKBA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AKBA · Stock Price

USD 1.18-1.37 (-53.73%)

Market Cap: $309.8M

Historical price data

Market Cap: $309.8MPipeline: 40 drugs (13 Phase 3)Patents: 20Founded: 2007HQ: Cambridge, United States

Sector Ranking#234 in Small Molecule Drugs

Overview

Akebia Therapeutics is a commercial-stage biopharma with a mission to better the lives of those impacted by kidney disease through innovative therapeutics. The company has achieved significant milestones, including the FDA approval and commercialization of two oral HIF-PHI products, vadadustat and Auryxia, establishing it as a trusted leader in nephrology. Its strategy centers on maximizing the value of its commercial portfolio, advancing its late-stage pipeline in kidney disease complications, and leveraging its fully integrated operational model and deep renal community expertise for sustainable growth.

RenalMetabolic

Technology Platform

Proprietary hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) platform, leveraging Nobel Prize-winning science to develop oral small-molecule therapeutics that mimic the body's physiological response to low oxygen.

Pipeline

40

40 drugs in pipeline13 in Phase 3

Drug	Indication	Stage
Ferric Citrate 1 gram Oral Tablet + Standard of care phospha...	Hyperphosphatemia	Approved
Vadadustat + Darbepoetin alfa	Anemia	Phase 3
Vadadustat + Darbepoetin alfa	Anemia	Phase 3
Vadadustat	Anemia of Chronic Kidney Disease	Phase 3
Vadadustat + Darbepoetin alfa	Anemia	Phase 3

Funding History

4

Total raised:$269M

IPO$108MUndisclosedFeb 7, 2014

Series C$78MUndisclosedDec 15, 2011

Series B$48MNovartis Venture FundJun 15, 2009

Series A$35MOxford Bioscience PartnersJan 15, 2007

FDA Approved Drugs

2

VAFSEONDAMar 27, 2024

AURYXIANDASep 5, 2014

Opportunities

The primary opportunity is displacing the multi-billion dollar injectable ESA market with oral vadadustat, offering a more physiological treatment for CKD anemia.

Additionally, leveraging the HIF platform to address other serious complications of kidney disease represents a significant long-term value creation avenue.

Risk Factors

Key risks include intense commercial competition from established injectables and other oral HIF-PHIs, potential challenges achieving profitability amid launch costs, and pipeline concentration on two core products.

Regulatory and clinical risks persist for future pipeline expansion.

Competitive Landscape

Akebia competes directly with injectable ESAs (Amgen, J&J) and other oral HIF-PHIs like GSK's daprodustat in the anemia market. In hyperphosphatemia, Auryxia faces competition from multiple phosphate binders. Success depends on commercial execution and differentiation of its oral therapies.